[Association of RAS Mutations in Circulating Cell-free DNA in the Plasma with Clinicopathological Features of Colorectal Cancer]

Overview

Journal Nan Fang Yi Ke Da Xue Xue Bao

Specialty General Medicine

Date 2017 Jul 25

PMID 28736377

Authors

Jing Wu

Li-Rong Zhao

Xiu-Qiang Lin

Fen Feng

Yong-Chang Chen

Wei-Ying Deng

Yan-Ming Deng

Wei Wang

Affiliations

Soon will be listed here.

Abstract

Objective: To detect RAS mutations in the circulating cell-free DNA (cfDNA) in the plasma and explore the their correlation with the clinicopathological features in patients with colorectal cancer.

Methods: Real-time PCR was used to detect RAS mutations in plasma cfDNA and matched tumor tissue DNA samples from 71 colorectal cancer patients. The correlation of RAS mutations with the clinicopathological features of the patients were analyzed.

Results: Of the 71 patients with colorectal cancer, 23 (32.39%) showed RAS mutations in the cfDNA and 36 (50.7%) showed RAS mutations in tumor tissue DNA, with a concordance rate of 76.06% in the results between the two samples (Kappa=0.523). RAS mutations in the cfDNA were not related to the patients' age (P=0.072), gender (P=0.320), tumor stage (IVa and IVb, P=0.450), primary tumor position (P=0.324), lung metastasis (P=0.237), CEA level (P=0.284) or CA199 level (P=0.427). The positivity rate of RAS mutations in plasma cfDNA was significantly higher in patients with liver metastasis than those without liver metastasis (P=0.045).

Conclusion: Plasma cfDNA can be a reliable source of diagnostic DNA to replace the tumor tissue DNA for diagnosis of RAS mutations. RAS mutations in plasma cfDNA occur more frequently in colorectal cancer patients with liver metastasis.

References

Sepulveda A, Hamilton S, Allegra C, Grody W, Cushman-Vokoun A, Funkhouser W . Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2017; 141(5):625-657. DOI: 10.5858/arpa.2016-0554-CP. View

Spindler K, Pallisgaard N, Appelt A, Andersen R, Schou J, Nielsen D . Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. Eur J Cancer. 2015; 51(17):2678-85. DOI: 10.1016/j.ejca.2015.06.118. View

Wang J, Hsieh J, Chang M, Huang T, Chen F, Cheng T . Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg. 2004; 28(7):721-6. DOI: 10.1007/s00268-004-7366-8. View

Kim M, Lee H, Kim J, Kim Y, Kwon J, Lee J . Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer. 2012; 12:347. PMC: 3488475. DOI: 10.1186/1471-2407-12-347. View

Kuo Y, Chen J, Fan C, Li Y, Chan E . Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin Chim Acta. 2014; 433:284-9. DOI: 10.1016/j.cca.2014.03.024. View

Hecht J, Douillard J, Schwartzberg L, Grothey A, Kopetz S, Rong A . Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat Rev. 2015; 41(8):653-9. DOI: 10.1016/j.ctrv.2015.05.008. View

Spindler K, Pallisgaard N, Vogelius I, Jakobsen A . Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 2012; 18(4):1177-85. DOI: 10.1158/1078-0432.CCR-11-0564. View

Xu J, Liu X, Ge F, Lin L, Wang Y, Sharma M . KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. J Exp Clin Cancer Res. 2014; 33:104. PMC: 4272803. DOI: 10.1186/s13046-014-0104-7. View

Hsieh J, Lin S, Chang M, Chen F, Lu C, Huang T . APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Am Surg. 2005; 71(4):336-43. View

10.

Allegra C, Rumble R, Hamilton S, Mangu P, Roach N, Hantel A . Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2015; 34(2):179-85. DOI: 10.1200/JCO.2015.63.9674. View

11.

Frattini M, Gallino G, Signoroni S, Balestra D, Battaglia L, Sozzi G . Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann N Y Acad Sci. 2006; 1075:185-90. DOI: 10.1196/annals.1368.025. View

12.

Douillard J, Oliner K, Siena S, Tabernero J, Burkes R, Barugel M . Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013; 369(11):1023-34. DOI: 10.1056/NEJMoa1305275. View

13.

Heinemann V, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S . FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10):1065-75. DOI: 10.1016/S1470-2045(14)70330-4. View

14.

Van Cutsem E, Lenz H, Kohne C, Heinemann V, Tejpar S, Melezinek I . Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015; 33(7):692-700. DOI: 10.1200/JCO.2014.59.4812. View

15.

Oltedal S, Aasprong O, Moller J, Korner H, Gilje B, Tjensvoll K . Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy. Int J Colorectal Dis. 2011; 26(10):1271-7. DOI: 10.1007/s00384-011-1233-5. View

16.

Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A . Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013; 10(8):472-84. DOI: 10.1038/nrclinonc.2013.110. View

17.

Diaz Jr L, Williams R, Wu J, Kinde I, Hecht J, Berlin J . The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486(7404):537-40. PMC: 3436069. DOI: 10.1038/nature11219. View

18.

Knijn N, Mekenkamp L, Klomp M, Vink-Borger M, Tol J, Teerenstra S . KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011; 104(6):1020-6. PMC: 3065268. DOI: 10.1038/bjc.2011.26. View

19.

Ai B, Liu H, Huang Y, Peng P . Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Oncotarget. 2016; 7(28):44583-44595. PMC: 5190120. DOI: 10.18632/oncotarget.10069. View

20.

Boissiere-Michot F, Lopez-Crapez E, Frugier H, Berthe M, Ho-Pun-Cheung A, Assenat E . KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment. Mod Pathol. 2012; 25(5):731-9. DOI: 10.1038/modpathol.2011.210. View